Tan Sven-Jean, Cai Michael Mx
Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.
Nephrology (Carlton). 2017 Mar;22 Suppl 2:14-18. doi: 10.1111/nep.13015.
The current management of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) relies largely on clinical judgement and assessment of biochemical parameters including serum calcium, phosphate and intact parathyroid hormone concentrations. In the past two decades, there has been a leap in the understanding of the pathophysiology of CKD-MBD, leading to the discovery of novel biomarkers. The potential utility of these markers in this clinical setting is an area of intense investigation. In the absence of any guidelines aiding the clinician's understanding and application of these markers, we summarise the current available literature surrounding fibroblast growth factor-23, α-Klotho, sclerostin and serum calcification propensity testing and their respective assays in the context of CKD-MBD management.
慢性肾脏病-矿物质和骨异常（CKD-MBD）的当前管理很大程度上依赖于临床判断以及对包括血清钙、磷和完整甲状旁腺激素浓度在内的生化参数的评估。在过去二十年中，对CKD-MBD病理生理学的理解有了飞跃，从而发现了新的生物标志物。这些标志物在这种临床环境中的潜在用途是一个深入研究的领域。在缺乏帮助临床医生理解和应用这些标志物的指南的情况下，我们总结了当前围绕成纤维细胞生长因子-23、α-klotho、骨硬化蛋白和血清钙化倾向检测及其在CKD-MBD管理背景下各自检测方法的现有文献。
